Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, GeneFerm Biotechnology Co's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
GeneFerm Biotechnology Co FCF Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, GeneFerm Biotechnology Co's FCF Margin % distribution charts can be found below:
* The bar in red indicates where GeneFerm Biotechnology Co's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
GeneFerm Biotechnology Co (ROCO:1796) has a FCF Margin % of 7.92% as of Dec. 2025. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on GeneFerm Biotechnology Co and its competitors. According to the industry distribution chart, GeneFerm Biotechnology Co ranks #253 out of 960 companies in the Drug Manufacturers industry, placing it in the top 26.4%.
Is GeneFerm Biotechnology Co's FCF Margin % too high?
GeneFerm Biotechnology Co's current FCF Margin % is 7.92%. The Drug Manufacturers industry median FCF Margin % is 2.59. GeneFerm Biotechnology Co's value of 7.92% is 206.4% above this industry median. Based on the distribution chart, GeneFerm Biotechnology Co ranks #253 out of 960 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, GeneFerm Biotechnology Co has a GF Score™ of 65/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does GeneFerm Biotechnology Co's FCF Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, GeneFerm Biotechnology Co ranks #253 out of 960 companies for FCF Margin %. This puts GeneFerm Biotechnology Co in the upper half of its industry. The industry median FCF Margin % is 2.59. GeneFerm Biotechnology Co's value of 7.92% is 206.4% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Drug Manufacturers company?
The median FCF Margin % among Drug Manufacturers companies is 2.59, based on 960 companies in the industry. Companies in the top quartile (top 25%) have a FCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. GeneFerm Biotechnology Co's current FCF Margin % of 7.92% is 206.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on GeneFerm Biotechnology Co and its competitors. For the Drug Manufacturers industry, the median FCF Margin % is 2.59 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. GeneFerm Biotechnology Co's current FCF Margin % is 7.92%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GeneFerm Biotechnology Co stock overvalued right now?
Based on GuruFocus' analysis, GeneFerm Biotechnology Co (ROCO:1796) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$59.04, compared to a current price of NT$31.40 — trading 46.8% below its estimated fair value. The current FCF Margin % is 7.92% and 206.4% above the Drug Manufacturers industry median of 2.59. GeneFerm Biotechnology Co's overall GF Score™ is 65/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For GeneFerm Biotechnology Co (ROCO:1796), the current FCF Margin % is 7.92% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is GeneFerm Biotechnology Co (ROCO:1796) Overvalued in 2026?
Based on GuruFocus' analysis, GeneFerm Biotechnology Co stock appears to be undervalued.
The current stock price of NT$31.40 is trading 46.8% below its estimated GF Value™ of NT$59.04.
GuruFocus considers GeneFerm Biotechnology Co to be Significantly Undervalued.
Key valuation signals for ROCO:1796:
FCF Margin %: 7.92%
GF Value™: NT$59.04 vs. price of NT$31.40 (46.8% below fair value)
Industry Position: 206.4% above the Drug Manufacturers median (#253 of 960)
No single metric tells the full story. See the ROCO:1796 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
GeneFerm Biotechnology Co Ltd is a fermentation company based in Taiwan. It is engaged in manufacturing health food and supplements which include Fermented Microbial products, Fermented Fungi products, Probiotics and Extraction, and Concentration products among others.
65GF Score
Get the complete analysis for ROCO:1796
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:1796 has been successfully added to your 
